Tadalafil for severe lung blood-pressure problems from COPD
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This study tests whether tadalafil can improve outcomes for people with severe pulmonary hypertension caused by COPD (chronic lung disease). It compares how you do with tadalafil versus standard care, focusing on breathing symptoms and how well your heart and lungs cope.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 84 years old when you join
- Your COPD causes ongoing airflow blockage, shown by breathing test results (FEV1/FVC under 0.70 after inhaler use)
- You have severe pulmonary hypertension confirmed by heart/lung pressure tests, with specific measurements (mPAP over 20, normal wedge pressure, and high lung-vessel resistance)
- Your breathing shortness of breath is moderate to severe (WHO functional class II to IV)
- You have not taken certain pulmonary hypertension medicines recently (no PDE5 pills like sildenafil/tadalafil in the past, and no other listed PH drugs in the past 3 months)
- Your COPD treatments and, if needed, your home oxygen setup have been stable for at least 1 month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether tadalafil can improve breathlessness in people with COPD and pulmonary hypertension (high blood pressure in the lungs). It may help you breathe more easily if your symptoms are driven by this specific lung circulation problem.
This Phase 2 trial tests whether sildenafil tablets can improve exercise ability, shortness of breath, and heart-lung function in people with COPD. It also compares against people without COPD to better understand how sildenafil affects breathing tests.
This trial tests whether an inhaled medication called treprostinil (which helps open blood vessels in the lungs) can improve exercise ability in people who get high blood pressure in the lungs only during exercise. Participation involves taking the medication and doing exercise tests to see how well you do.
This study tests an inhaled powder medication called TPIP (treprostinil palmitil inhalation powder) to see if it can improve symptoms and exercise ability in people who have both interstitial lung disease and pulmonary hypertension. The study will compare TPIP against a placebo (a dummy treatment without the active drug) to understand how well it works and if it is safe.
This study tests an oral tablet called RSS0343 for people with moderate to severe COPD. It aims to see if the tablet can improve lung function and reduce flare-ups when added to your current breathing treatments.
This trial compares starting with two oral medications versus one for people newly diagnosed with pulmonary arterial hypertension (PAH) who also have conditions like high blood pressure, diabetes, obesity, or heart disease. The goal is to see if a two-drug approach works better for patients with these additional health issues.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.